Exportin XPO6 upregulation activates the TLR2/MyD88/NF-κB signaling by facilitating TLR2 mRNA nuclear export in COPD pulmonary monocytes.

COPD Lung inflammation NF-κB Pulmonary monocytes Toll-like receptors

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 26 03 2024
revised: 01 05 2024
accepted: 16 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

Chronic obstructive pulmonary disease (COPD) poses a significant health threat characterized by lung inflammation primarily triggered by pulmonary monocytes. Despite the centrality of inflammation in COPD, the regulatory mechanisms governing this response remain elusive, presenting a challenge for anti-inflammatory interventions. In this study, we assessed the expression of exportins in COPD mouse models, revealing a notable upregulation of XPO6 in the mouse lung (P = 0.0011). Intriguingly, we observed a consistent upregulation of XPO6 in pulmonary monocytes from both human and mouse COPD subjects (P < 0.0001). Furthermore, in human lung tissue, XPO6 expression exhibited a positive correlation with TLR2 expression (P = 0). In vitro investigations demonstrated that XPO6 enhances TLR2 expression, activating the MyD88/NF-κB inflammatory signaling pathway. This activation, in turn, promotes the secretion of pro-inflammatory cytokines such as TNFα, IL-6, and IL-1β in monocytes. Mechanistically, XPO6 facilitates the nuclear export of TLR2 mRNA, ensuring its stability and subsequent protein expression in monocytes. In conclusion, our findings unveil that the upregulation of XPO6 in COPD pulmonary monocytes activates the MyD88/NF-κB inflammatory signaling pathway by facilitating the nuclear export of TLR2 mRNA, thereby identifying XPO6 as a promising therapeutic target for anti-inflammatory interventions in COPD.

Identifiants

pubmed: 38788453
pii: S1567-5769(24)00830-0
doi: 10.1016/j.intimp.2024.112310
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112310

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yuting Wu (Y)

Department of Respiratory and Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, Guangdong, China; Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China. Electronic address: yutingwu66@126.com.

Yanni Gou (Y)

Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China.

Tao Wang (T)

Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China.

Ping Li (P)

Department of Respiratory and Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, Guangdong, China.

Yongqiang Li (Y)

Department of Respiratory and Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, Guangdong, China.

Xing Lu (X)

Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong, China.

Weifeng Li (W)

Department of Respiratory and Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou 510010, Guangdong, China. Electronic address: lwf980622@126.com.

Zhifeng Liu (Z)

Department of Medicine Intensive Care Unit, General Hospital of Southern Theatre Command of PLA, Guangzhou 510010, Guangdong, China; Guangdong Branch Center, National Clinical Research Center for Geriatric Diseases (Chinese PLA General Hospital), Guangzhou 510010, Guangdong, China. Electronic address: zhifengliu7797@163.com.

Classifications MeSH